Friday, April 4, 2025
spot_img

Valeo – voting rights March 2025

PRESS RELEASE
Paris, April 3, 2025

Information on the total number of voting rights
and shares forming the share capital
(Article L.233-8 II of the French Commercial Code and
Article 223-16 of the General Regulation of the French Financial Markets Authority)

Date

Issued capital

Par value

Total number of shares

Total number of voting rights
Theoretical* Exercisable**

March 31, 2025

€ 244,633,504 € 1 244,633,504 274,270,662 273,803,785

*In accordance with Article 223-11 of the General Regulation of the French Financial Markets Authority, the total number of theoretical voting rights is calculated on the basis of all shares to which voting rights are attached, including shares deprived of voting rights.
** The total number of exercisable voting rights is calculated without taking into account shares deprived of voting rights.

About Valeo

As a technology company and partner to all automakers and new mobility players, Valeo is innovating to make mobility cleaner, safer and smarter. Valeo enjoys technological and industrial leadership in electrification, driving assistance systems, reinvention of the interior experience and lighting everywhere. These four areas, vital to the transformation of mobility, are the Group’s growth drivers.
Valeo in figures: 21.5 billion euros in sales in 2024 | 106,100 employees, 28 countries, 155 plants, 46 research and development centers, 18 distribution platforms at December 31, 2024.

Valeo is listed on the Paris Stock Exchange.

Attachment

  • PR_Valeo_voting rights_March 2025

Powered by SlickText.com

Hot this week

Bunker Hill Announces Election to Issue Shares in Satisfaction of Debenture Interest Payment Obligations

KELLOGG, Idaho and VANCOUVER, British Columbia, April 03,...

Brookfield Infrastructure Announces the Acquisition of Colonial Enterprises

BROOKFIELD, News, April 03, 2025 (GLOBE NEWSWIRE)...

Lianhe Sowell Debuts on Nasdaq, Accelerating Business Growth Ambitions and Industry Revolution

SHENZHEN, China, April 03, 2025 (GLOBE NEWSWIRE)...

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Strategic collaboration with LaunXP for the development of vebreltinib...

AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE)...

Topics

spot_img

Related Articles

Popular Categories

spot_img